Home
VRTX
VRTX News

Latest Vertex Pharmaceuticals Incorporated (VRTX) News on November 18, 2025

Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target

Insider Monkey

9 hours ago

Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target

MT Newswires

a day ago

Vertex Pharmaceuticals Insider Sold Shares Worth $32,292,320, According to a Recent SEC Filing

1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November

Motley Fool

a day ago

1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November

My 3 Favorite Stocks to Buy Right Now

Motley Fool

2 days ago

My 3 Favorite Stocks to Buy Right Now

MT Newswires

4 days ago

Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $500 From $430, Maintains Buy Rating

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

The Fly

5 days ago

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off

StockStory

6 days ago

1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off

MT Newswires

6 days ago

Rothschild & Co Redburn Adjusts PT on Vertex Pharmaceuticals to $545 From $530, Keeps Buy Rating

Morningstar Research

7 days ago

Analyst Report: CRISPR Therapeutics AG

The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress

Simply Wall St.

8 days ago

The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

GlobeNewswire

8 days ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call

StockStory

9 days ago

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Business Wire

10 days ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

MT Newswires

11 days ago

UBS Adjusts Price Target on Vertex Pharmaceuticals to $546 From $553, Maintains Buy Rating

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Zacks

11 days ago

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges

StockStory

13 days ago

2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges

Morningstar Research

13 days ago

Analyst Report: Royalty Pharma plc

Morningstar Research

13 days ago

Analyst Report: Vertex Pharmaceuticals Incorporated

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

Zacks

13 days ago

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality

Simply Wall St.

14 days ago

Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality

Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat

Investor's Business Daily

14 days ago

Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

Zacks

14 days ago

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

MT Newswires

14 days ago

Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $466 From $471, Maintains Market Perform Rating

MT Newswires

14 days ago

Barclays Adjusts Price Target on Vertex Pharmaceuticals to $414 From $408, Maintains Equalweight Rating

MT Newswires

14 days ago

Stifel Adjusts Price Target on Vertex Pharmaceuticals to $445 From $455, Maintains Hold Rating

MT Newswires

14 days ago

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $604 From $603, Maintains Buy Rating

VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook

StockStory

14 days ago

VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook

Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention

GlobeNewswire

14 days ago

Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention

MT Newswires

14 days ago

RBC Lowers Price Target on Vertex Pharmaceuticals to $415 From $423, Keeps Sector Perform Rating

Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

15 days ago

Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon

Motley Fool

15 days ago

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon

McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week

The Wall Street Journal

15 days ago

McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week

Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments

Simply Wall St.

16 days ago

Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments

My Top Growth Stock to Buy in November

Motley Fool

16 days ago

My Top Growth Stock to Buy in November

Palantir, AMD, Pfizer, Robinhood, McDonald’s, and Many More Stocks to Watch This Week

Barrons.com

16 days ago

Palantir, AMD, Pfizer, Robinhood, McDonald’s, and Many More Stocks to Watch This Week

Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week

Yahoo Finance

16 days ago

Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week

Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect

StockStory

17 days ago

Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect

SNAP benefits expire, open enrollment, earnings: What to Watch

Yahoo Finance Video

18 days ago

SNAP benefits expire, open enrollment, earnings: What to Watch

Rigel Gears Up to Report Q3 Earnings: Here's What to Expect

Zacks

18 days ago

Rigel Gears Up to Report Q3 Earnings: Here's What to Expect

Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain.

Barrons.com

19 days ago

Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain.

Vertex Pharmaceuticals (VRTX) Stock Moves -1.23%: What You Should Know

Zacks

20 days ago

Vertex Pharmaceuticals (VRTX) Stock Moves -1.23%: What You Should Know

Amgen's Q3 Earnings in the Cards: Here's What to Expect

Zacks

20 days ago

Amgen's Q3 Earnings in the Cards: Here's What to Expect

Exploring Analyst Estimates for Vertex (VRTX) Q3 Earnings, Beyond Revenue and EPS

Zacks

20 days ago

Exploring Analyst Estimates for Vertex (VRTX) Q3 Earnings, Beyond Revenue and EPS

H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)

Insider Monkey

21 days ago

H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate

Simply Wall St.

21 days ago

Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Zacks

21 days ago

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know

Zacks

21 days ago

Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These

Motley Fool

21 days ago

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Business Wire

22 days ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial

Barrons.com

22 days ago

Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Zacks

22 days ago

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks

22 days ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030

Motley Fool

22 days ago

Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030

Did FDA Progress on Povetacicept and New Data for ALYFTREK Just Shift Vertex’s (VRTX) Investment Narrative?

Simply Wall St.

a month ago

Did FDA Progress on Povetacicept and New Data for ALYFTREK Just Shift Vertex’s (VRTX) Investment Narrative?

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Business Wire

a month ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)

Insider Monkey

a month ago

Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

a month ago

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

2 Growth Stocks to Invest $1,000 in Right Now

Motley Fool

a month ago

2 Growth Stocks to Invest $1,000 in Right Now

A Closer Look at Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Stability

Simply Wall St.

a month ago

A Closer Look at Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Stability

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Zacks

a month ago

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

MT Newswires

a month ago

Goldman Sachs Cuts Vertex Pharmaceuticals Price Target to $603 From $624, Buy Rating Kept

MT Newswires

a month ago

Vertex Pharma Says FDA Grants Rolling Review of Povetacicept Application for IgA Nephropathy

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Business Wire

a month ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Vertex Pharmaceuticals: Commercial Pipeline Is Stronger Than What The Market Thinks

GuruFocus.com

a month ago

Vertex Pharmaceuticals: Commercial Pipeline Is Stronger Than What The Market Thinks

Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

Barchart

a month ago

Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Zacks

a month ago

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Adtalem, Google Cloud to launch AI credential program for healthcare professionals

Reuters

a month ago

Adtalem, Google Cloud to launch AI credential program for healthcare professionals

2 Unstoppable Growth Stocks to Buy During a Market Crash

Motley Fool

a month ago

2 Unstoppable Growth Stocks to Buy During a Market Crash

Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market

Zacks

a month ago

Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market

Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025?

Simply Wall St.

a month ago

Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025?

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Zacks

a month ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors

Business Wire

a month ago

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors

CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?

Zacks

a month ago

CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?

Morningstar Research

a month ago

Analyst Report: Vertex Pharmaceuticals Incorporated

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Zacks

a month ago

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

MT Newswires

a month ago

JPMorgan Adjusts PT on Vertex Pharmaceuticals to $530 From $517, Maintains Overweight Rating

MT Newswires

a month ago

RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $405, Keeps Sector Perform Rating

The Smartest Growth Stock to Buy With $500 Right Now

Motley Fool

a month ago

The Smartest Growth Stock to Buy With $500 Right Now

Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?

StockStory

a month ago

Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Business Wire

a month ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet?

Insider Monkey

a month ago

What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

a month ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

1 Healthcare Stock with Exciting Potential and 2 Facing Challenges

StockStory

a month ago

1 Healthcare Stock with Exciting Potential and 2 Facing Challenges

2 Beaten-Down Stocks Primed for a Comeback

Motley Fool

a month ago

2 Beaten-Down Stocks Primed for a Comeback

Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts

Zacks

a month ago

Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts

Vertex Pharmaceuticals (VRTX): Assessing Valuation as Shares Hold Steady and Long-Term Prospects Remain Key

Simply Wall St.

2 months ago

Vertex Pharmaceuticals (VRTX): Assessing Valuation as Shares Hold Steady and Long-Term Prospects Remain Key

3 Growth Stocks That Could Be 10-Baggers in 10 Years

Motley Fool

2 months ago

3 Growth Stocks That Could Be 10-Baggers in 10 Years

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Zacks

2 months ago

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Vertex Pharmaceuticals (VRTX) Highlights Pipeline Progress at BofA Global Healthcare Conference

Insider Monkey

2 months ago

Vertex Pharmaceuticals (VRTX) Highlights Pipeline Progress at BofA Global Healthcare Conference

MT Newswires

2 months ago

Citigroup Adjusts Price Target on Vertex Pharmaceuticals to $575 From $550, Maintains Buy Rating

Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?

Pharma Voice

2 months ago

Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?

2 S&P 500 Stocks to Research Further and 1 We Avoid

StockStory

2 months ago

2 S&P 500 Stocks to Research Further and 1 We Avoid

What Vertex Pharmaceuticals (VRTX)'s FDA Breakthrough for Povetacicept Means for Kidney Disease Pipeline

Simply Wall St.

2 months ago

What Vertex Pharmaceuticals (VRTX)'s FDA Breakthrough for Povetacicept Means for Kidney Disease Pipeline

Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing

Zacks

2 months ago

Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing

Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?

Zacks

2 months ago

Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Zacks

2 months ago

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Zacks

2 months ago

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

MT Newswires

2 months ago

Vertex Says FDA Granted Breakthrough Therapy Status for Immunoglobulin A Nephropathy Treatment

Vertex Announces Key Advancements Across Kidney Portfolio

Business Wire

2 months ago

Vertex Announces Key Advancements Across Kidney Portfolio

MT Newswires

2 months ago

Leerink Partners Upgrades Vertex Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $456 From $458

Share on Social Networks: